Bamlanivimab: What you should know
Many potential drugs and vaccines for use against COVID-19 are being evaluated in Canada and around the world. We’re closely tracking all potential drugs and vaccines in development.
You can search the complete list of applications received for COVID-19-related drugs and vaccines and their status.
Bamlanivimab is a monoclonal antibody directed against the SARS-CoV-2 spike protein. It’s used in health care facilities such as hospitals, as it is given by infusion into the veins of patients.
Bamlanivimab is designed to block the SARS-CoV-2 virus from attaching to and entering human cells. It may prevent symptoms from becoming worse and reduce hospitalizations in people who are infected with COVID-19 and are at high risk of becoming very sick.
Health Canada authorized this drug in November 2020 under the interim order respecting the importation, sale and advertising of drugs for use in relation to COVID-19. It’s sold in Canada by Eli Lilly Canada, Inc.
Bamlanivimab is used to treat adults and youth 12 years of age or older with mild to moderate COVID-19 who:
- weigh at least 40 kg and
- are at high risk of progressing to severe COVID-19 illness and/or hospitalization
Find detailed technical information about bamlanivimab, such as the product monograph and our regulatory decision summary, in the COVID-19 vaccines and treatments regulatory portal.
Report a problem or mistake on this page
- Date modified: